Furthermore, with the evidence from a recent clinical trial suggesting benefit of immunotherapies in MMR deficient solid cancers regardless of the tumour location [8], the application of the current assay to non-CRC MSI-H tumours could be envisaged. Here, MRC1 is linked to colorectal carcinoma.